ABL1 is altered in 1.51% of leukemia patients [2].

ABL1 is an inclusion eligibility criterion in 2 clinical trials for leukemia, of which 2 are open and 0 are closed. Of the trials that contain ABL1 status and leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

AFF1 is altered in 0.16% of leukemia patients [2].

AFF1 is an inclusion eligibility criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains AFF1 status and leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

ASXL1 is altered in 14.48% of leukemia patients [2].

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains ASXL1 status and leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

BCR is altered in 1.84% of leukemia patients [2].

BCR is an inclusion eligibility criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains BCR status and leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

DEK is an inclusion eligibility criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains DEK status and leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 is altered in 0.54% of leukemia patients [2].

ERBB2 is an inclusion eligibility criterion in 2 clinical trials for leukemia, of which 1 is open and 1 is closed. Of the trials that contain ERBB2 status and leukemia as inclusion criteria, 2 are phase 1 (1 open) [3].

FLT1 is altered in 0.35% of leukemia patients [2].

FLT1 is an inclusion eligibility criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FLT3 is altered in 14.35% of leukemia patients [2].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

IDH1 is altered in 6.62% of leukemia patients [2].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for leukemia, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

IDH2 is altered in 9.46% of leukemia patients [2].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for leukemia, of which 0 are open and 1 is closed. Of the trial that contains IDH2 status and leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

KIT is altered in 1.95% of leukemia patients [2].

KIT is an inclusion eligibility criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains KIT status and leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

KMT2A is altered in 2.52% of leukemia patients [2].

KMT2A is an inclusion eligibility criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

MECOM is altered in 1.15% of leukemia patients [2].

MECOM is an inclusion eligibility criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

NUP214 is an inclusion eligibility criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains NUP214 status and leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

PBX1 is an inclusion eligibility criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains PBX1 status and leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA is altered in 0.38% of leukemia patients [2].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RET is altered in 0.33% of leukemia patients [2].

RET is an inclusion eligibility criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains RET status and leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains RPN1 status and leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

RUNX1 is altered in 14.36% of leukemia patients [2].

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

TCF3 is altered in 0.43% of leukemia patients [2].

TCF3 is an inclusion eligibility criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains TCF3 status and leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

TP53 is altered in 13.38% of leukemia patients [2].

TP53 is an inclusion eligibility criterion in 2 clinical trials for leukemia, of which 1 is open and 1 is closed. Of the trials that contain TP53 status and leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].